Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Br J Dermatol, 2020.
Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group.
Read publication: Br J Dermatol
Related
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with mo...
Associations between psoriatic arthritis and mental health among patients with psoriasis: A replicat...
Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-b...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
0 Comments